CCL20 and autoimmune disease: According to Galon J’s study (20), the immune microenvironment of BM is not inherently “hot”, but it can be targeted by inhibiting the CCL20–CCR6 axis, which takes part in immune suppression and a lot of inflammatory and immune-activated states, including autoimmune disease (21).